Horizon Therapeutics Plc HZNP

NAS: HZNP | ISIN: IE00BQPVQZ61   17/09/2024
116,30 USD (0,00%)
(0,00%)   17/09/2024

13 september 2023 · Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata · Persbericht

1 september 2023 · Amgen And Horizon Therapeutics Plc Resolve Ftc Lawsuit, Clearing Path To Close Acquisition · Persbericht

18 april 2023 · Horizon Therapeutics plc et le Massachusetts Institute of Technology (MIT) Solve annoncent le lancement du troisième prix annuel Horizon pour encourager le développement de solutions durables dans la recherche et les soins au service de la communauté des maladies rares · Persbericht

27 oktober 2022 · Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis · Persbericht

15 augustus 2022 · Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases · Persbericht

11 januari 2022 · ACELYRIN Appoints Melanie Gloria as Chief Operating Officer · Persbericht

21 september 2021 · HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline · Persbericht

21 april 2021 · HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout · Persbericht

21 februari 2021 · (VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are Shareholders Getting a Fair Deal? · Persbericht

1 februari 2021 · SHAREHOLDER ALERT: WeissLaw LLP Investigates Viela Bio, Inc. · Persbericht

1 februari 2021 · (VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are Shareholders Getting a Fair Deal? · Persbericht

Mijn selecties